Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.
Phil McEwanJason A DavisPeter D GabbDavid C WheelerEllen BurgessGlenn M ChertowRicardo Correa-RotterKouichi TamuraSalvatore BaroneJuan Jose Garcia SanchezPublished in: Clinical kidney journal (2024)
Treatment with dapagliflozin may be cost-effective for patients across a wider spectrum of estimated glomerular filtration rates and albuminuria than previously demonstrated, with or without type 2 diabetes, in the UK, Spanish, Italian and Japanese healthcare systems.
Keyphrases
- end stage renal disease
- type diabetes
- healthcare
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- clinical trial
- cardiovascular disease
- study protocol
- prognostic factors
- cross sectional
- randomized controlled trial
- glycemic control
- patient reported outcomes
- phase iii
- insulin resistance
- phase ii
- social media
- high glucose